Boston Scientific Counters J&J In “Perception Battle” With New Taxus Data

Boston Scientific expects new clinical trial data presented at the Paris Course on Revascularization (PCR) May 24 to help reverse an ongoing shift of the drug-eluting stent market toward Johnson & Johnson/Cordis